Vanda raises cash in anticipation of tasimelteon approval
This article was originally published in Scrip
Vanda Pharmaceuticals is taking advantage of a spike in its stock price to sell 4.68 million shares following recent US FDA acceptance of its new drug application (NDA) for tasimelteon and the regulator's decision to grant priority review for the sleep disorder drug.
You may also be interested in...
Public Company Edition: After an initial hit to valuations from COVID-19, massive amounts of money have been raised by drug developers, such as argenx with a $862.5m stock sale. However, only two IPOs launched in the US in May, including ADC with a $267m offering.
Kynmobi is an important approval for parent company Sumitomo Dainippon ahead of the loss of exclusivity for Latuda. Sunovion hopes to launch after COVID-19 social distancing requirements ease.
Private Company Edition: Atea and Phlow receive big money for big COVID-19 problems – treatments and manufacturing capacity. Also, Cowen raises a $493m fund and antifungal developer Amplyx increases series C round to $90m, among other recent VC deals.